INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION IS SAFE AND WELL TOLERATED

被引：0
|
作者：
Allegretti, Jessica R.
McClure, Emma L.
Marcus, Jenna
Norton, Beth Ann
Hamilton, Matthew
Winter, Rachel
De Silva, Punyanganie
Friedman, Sonia
Korzenik, Joshua R.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1874
引用
收藏
页码：S461 / S461
页数：1
相关论文
共 50 条
  • [21] Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab
    Duveau, N.
    Nachury, M.
    Boualit, M.
    Gerard, R.
    Branche, J.
    Maunoury, V.
    Desreumaux, P.
    Pariente, B.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S320 - S320
  • [22] Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease
    Fedorak, RN
    Nielsen, OH
    Williams, NC
    Malchow, H
    Forbes, A
    Stein, B
    Wild, GE
    Lashner, B
    Renner, EL
    Buchman, A
    Hardi, R
    GASTROENTEROLOGY, 2001, 120 (05) : A127 - A127
  • [23] Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn's disease
    Zhu, Kouzhu
    Ding, Xiaoliang
    Xue, Ling
    Liu, Linsheng
    Wang, Yan
    Li, Yun
    Xi, Qinhua
    Pang, Xueqin
    Chen, Weichang
    Miao, Liyan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [24] Escalation of infliximab maintenance therapy in Crohn's disease
    Corman, Scott
    Issa, Mazen
    Beaulieu, Dawn B.
    Weber, Lydia R.
    Brandenburg, Heather
    Emmons, Jeanne
    Knox, Josh F.
    Skaros, Sue
    Thameem, Danish
    Binion, David G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S470 - S470
  • [25] Long term outcomes following de-escalation of dose-intensified ustekinumab in patients with Crohn's disease
    Demase, K.
    Smith, R. L.
    Luber, R.
    Taylor, K. M.
    Ward, M. G.
    Sparrow, M. P.
    Little, R. D.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1317 - I1317
  • [26] Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
    Hiroshi Nakase
    Motohiro Esaki
    Fumihito Hirai
    Taku Kobayashi
    Katsuyoshi Matsuoka
    Minoru Matsuura
    Makoto Naganuma
    Masayuki Saruta
    Kiichiro Tsuchiya
    Motoi Uchino
    Kenji Watanabe
    Tadakazu Hisamatsu
    Journal of Gastroenterology, 2023, 58 : 313 - 345
  • [27] Effectiveness of a Dose "De-Escalation" Strategy With Anti-TNF Drugs in Patients With Crohn's Disease (CD)
    Chaparro, Maria
    Acosta, Manuel Barreiro-de
    Garcia-Planella, Esther
    Domenech, Eugeni
    Bennejo, Fernando
    Calvet, Xavier
    Arranz, Maria Dolores Martin
    Monforn, David
    Gisbert, Javier P.
    GASTROENTEROLOGY, 2011, 140 (05) : S590 - S590
  • [28] De-escalation of Infliximab Maintenance Therapy from 8-to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease
    Papamichael, Konstantinos
    Karatzas, Pantelis
    Mantzaris, Gerasimos J.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (03): : 371 - 372
  • [29] Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021
    Nakase, Hiroshi
    Esaki, Motohiro
    Hirai, Fumihito
    Kobayashi, Taku
    Matsuoka, Katsuyoshi
    Matsuura, Minoru
    Naganuma, Makoto
    Saruta, Masayuki
    Tsuchiya, Kiichiro
    Uchino, Motoi
    Watanabe, Kenji
    Hisamatsu, Tadakazu
    TRADE Consensus Grp
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (04) : 313 - 345
  • [30] Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease
    Sako, M.
    Kawaguchi, T.
    Hirayama, A.
    Fukushi, G.
    Hayama, K.
    Fujiwara, T.
    Yoshimura, N.
    Takazoe, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S231 - S231
12345